OBJECTIVE: To compare non-HDL cholesterol (HDLc) and apolipoprotein B (apoB) in the identification of nonconventional high-risk dyslipidemic phenotypes in type 2 diabetic patients. RESEARCH DESIGN AND METHODS: Total cholesterol and triglycerides, HDLc, LDL cholesterol, non-HDLc, apolipoprotein B (apoB), and LDL size were determined in 122 type 2 diabetic patients (68% male, aged 59.6 +/- 9.7 years, and HbA(1c) 7.5% [range 5.2-16.0]). They were then classified as normo- and hypertriglyceridemic if their triglyceride concentrations were below/above 2.25 mmol/l, as normo/hyper-non-HDLc if non-HDLc concentrations were below/above 4.13 mmol/l, and as normo- and hyperapoB if apoB concentrations were below/above 0.97 g/l. Both classifications were compared (concordance assessed with the kappa index), and low HDLc and LDL phenotype B were identified in each category. RESULTS: A total of 26 patients were hypertriglyceridemic and 96 were normotriglyceridemic. All hypertriglyceridemic subjects had increased non-HDLc, whereas 24 had increased apoB (kappa= 0.95). In the normotriglyceridemic group, 44 had increased non-HDLc, 68 had increased apoB, and 25 of the 52 patients with normal non-HDLc had increased apoB (kappa= 0.587). Low HDLc and LDL phenotype B were similarly distributed into the equivalent categories. CONCLUSIONS: Non-HDLc and apoB are equivalent risk markers in hypertriglyceridemic patients, but apoB identifies additional patients with high-risk dyslipidemic phenotypes in normotriglyceridemic type 2 diabetic patients.
OBJECTIVE: To compare non-HDL cholesterol (HDLc) and apolipoprotein B (apoB) in the identification of nonconventional high-risk dyslipidemic phenotypes in type 2 diabeticpatients. RESEARCH DESIGN AND METHODS: Total cholesterol and triglycerides, HDLc, LDL cholesterol, non-HDLc, apolipoprotein B (apoB), and LDL size were determined in 122 type 2 diabeticpatients (68% male, aged 59.6 +/- 9.7 years, and HbA(1c) 7.5% [range 5.2-16.0]). They were then classified as normo- and hypertriglyceridemic if their triglyceride concentrations were below/above 2.25 mmol/l, as normo/hyper-non-HDLc if non-HDLc concentrations were below/above 4.13 mmol/l, and as normo- and hyperapoB if apoB concentrations were below/above 0.97 g/l. Both classifications were compared (concordance assessed with the kappa index), and low HDLc and LDL phenotype B were identified in each category. RESULTS: A total of 26 patients were hypertriglyceridemic and 96 were normotriglyceridemic. All hypertriglyceridemic subjects had increased non-HDLc, whereas 24 had increased apoB (kappa= 0.95). In the normotriglyceridemic group, 44 had increased non-HDLc, 68 had increased apoB, and 25 of the 52 patients with normal non-HDLc had increased apoB (kappa= 0.587). Low HDLc and LDL phenotype B were similarly distributed into the equivalent categories. CONCLUSIONS: Non-HDLc and apoB are equivalent risk markers in hypertriglyceridemicpatients, but apoB identifies additional patients with high-risk dyslipidemic phenotypes in normotriglyceridemic type 2 diabeticpatients.
Authors: B Fagerberg; S Edwards; T Halmos; J Lopatynski; H Schuster; S Stender; G Stoa-Birketvedt; S Tonstad; S Halldórsdóttir; I Gause-Nilsson Journal: Diabetologia Date: 2005-07-07 Impact factor: 10.122
Authors: G Bruno; F Merletti; A Biggeri; G Bargero; S Prina-Cerai; G Pagano; P Cavallo-Perin Journal: Diabetologia Date: 2006-03-09 Impact factor: 10.122
Authors: Jose Luis Sánchez-Quesada; Irene Vinagre; Elena De Juan-Franco; Juan Sánchez-Hernández; Rosa Bonet-Marques; Francisco Blanco-Vaca; Jordi Ordóñez-Llanos; Antonio Pérez Journal: Cardiovasc Diabetol Date: 2013-08-05 Impact factor: 9.951